Logos Global holds 1.285M shares (5.6%) of Avalo

Avalo Therapeutics reports that Logos Global and affiliated entities hold 1,285,000 shares, representing 5.6% of common stock.

Rhea-AI Filing Summary

Avalo Therapeutics reports that Logos Global and affiliated entities hold 1,285,000 shares, representing 5.6% of common stock. The reporting group states the position comprises 285,000 shares of Common Stock and options to acquire 1,000,000 shares, calculated using 22,788,452 shares outstanding as of March 18, 2026. The filing shows shared voting and shared dispositive power for 1,285,000 shares and zero sole voting or dispositive power. The reporting persons say they are filing jointly, disclaim group membership, and identify the Global Fund as holding the shares for investors.

Insights

Institutional Ownership Analyst

Logos Global reports a meaningful passive equity position (5.6%) via funds and affiliated entities.

The statement lists 1,285,000 shares beneficially owned across Logos Global, Logos Global GP, Logos Global Master Fund, Logos GP and Arsani William, with shared voting and dispositive power rather than sole control. The breakdown notes 285,000 actual shares plus 1,000,000 option rights.

Ownership is calculated on March 18, 2026. The filing disclaims group control; cash‑flow treatment and any planned dispositions are not stated in the excerpt.

Corporate Governance Specialist

Filing emphasizes passive position and non-control intent while disclosing shared authority.

The reporting persons certify the securities were "not acquired and are not held for the purpose of changing or influencing control" and disclaim group status. Shared voting/dispositive power suggests coordinated authority across affiliated entities rather than direct personal control.

Relevant items to watch in future filings include any Schedule 13D amendments or Form 4 disclosures if option exercises convert to additional shares.

Key Figures

Reported beneficial ownership: 1,285,000 shares Percent of class: 5.6% Shares outstanding used: 22,788,452 shares +2 more

5 metrics

Reported beneficial ownership 1,285,000 shares Amount beneficially owned by Logos Global and affiliates

Percent of class 5.6% Percent of common stock based on outstanding shares as of March 18, 2026

Shares outstanding used 22,788,452 shares Outstanding shares as of March 18, 2026 (source: Form 10-K)

Component: issued shares 285,000 shares Actual Common Stock reported as owned

Component: options 1,000,000 options Options to acquire Common Stock included in beneficial ownership calculation

Key Terms

beneficially owned, shared dispositive power, Schedule 13G

3 terms

beneficially owned regulatory

"The securities beneficially owned by the reporting persons consist of 285,000 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared Dispositive Power 1,285,000.00"

Schedule 13G regulatory

"EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Logos Global report in Avalo Therapeutics (AVTX)?

Logos Global and affiliates report beneficial ownership of 1,285,000 shares, equal to 5.6% of common stock based on 22,788,452 shares outstanding as of March 18, 2026. The position is shared across affiliated entities.

How is the 1,285,000-share position composed for AVTX?

The filing states the position includes 285,000 shares of Common Stock plus options to acquire 1,000,000 shares. The combination yields the reported beneficial ownership figure cited in the filing.

Does Logos Global claim control over Avalo Therapeutics?

No. The reporting persons certify the securities were not acquired to change control and they expressly disclaim membership in a group. They report shared voting and dispositive power, not sole control.

Which entities are named as reporting persons in the AVTX filing?

The filing names Logos Global Management LP, Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC and Arsani William as reporting persons, with the Global Fund holding shares for its investors.

What date is used to calculate the percent ownership in the AVTX filing?

The percent ownership is calculated using 22,788,452 shares outstanding as of March 18, 2026, as reported in the issuer's Form 10-K for the fiscal year ended December 31, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 01:02 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Avalo Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

05338F306

(CUSIP Number)

03/26/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

Logos Global Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,285,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,285,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,285,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of 285,000 shares of Common Stock and options to acquire 1,000,000 shares of Common Stock. The percentage is calculated based on 22,788,452 shares of Common Stock outstanding as of March 18, 2026, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2025.

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

Logos Global Management GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,285,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,285,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,285,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

HC, OO

Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of 285,000 shares of Common Stock and options to acquire 1,000,000 shares of Common Stock. The percentage is calculated based on 22,788,452 shares of Common Stock outstanding as of March 18, 2026, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2025.

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

Logos Global Master Fund LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,285,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,285,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,285,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of 285,000 shares of Common Stock and options to acquire 1,000,000 shares of Common Stock. The percentage is calculated based on 22,788,452 shares of Common Stock outstanding as of March 18, 2026, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2025.

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

Logos GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,285,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,285,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,285,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

HC, OO

Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of 285,000 shares of Common Stock and options to acquire 1,000,000 shares of Common Stock. The percentage is calculated based on 22,788,452 shares of Common Stock outstanding as of March 18, 2026, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2025.

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

Arsani William

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,285,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,285,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,285,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of 285,000 shares of Common Stock and options to acquire 1,000,000 shares of Common Stock. The percentage is calculated based on 22,788,452 shares of Common Stock outstanding as of March 18, 2026, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Avalo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087
Item 2.
(a)	Name of person filing: Logos Global Management LP ("Logos Global") Logos Global Management GP LLC ("Logos Global GP") Logos Global Master Fund LP ("Global Fund") Logos GP LLC ("Logos GP") Arsani William Logos Global is the investment adviser to investment funds, including Global Fund. Logos Global GP is the general partner of Logos Global. Logos GP is the general partner of Global Fund. Dr. William is a control person of Logos Global, Logos Global GP and Logos GP. The reporting persons are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Global Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
(b)	Address or principal business office or, if none, residence: One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129
(c)	Citizenship: See Item 4 of the cover sheet for each reporting person.
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 05338F306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Logos Global: 1,285,000 Logos Global GP: 1,285,000 Global Fund: 1,285,000 Logos GP: 1,285,000 Arsani William: 1,285,000
(b)	Percent of class: Logos Global: : 5.6% Logos Global GP: : 5.6% Global Fund: : 5.6% Logos GP: : 5.6% Arsani William: : 5.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Logos Global: 0 Logos Global GP: 0 Global Fund: 0 Logos GP: 0 Arsani William: 0
	(ii) Shared power to vote or to direct the vote: Logos Global: 1,285,000 Logos Global GP: 1,285,000 Global Fund: 1,285,000 Logos GP: 1,285,000 Arsani William: 1,285,000
	(iii) Sole power to dispose or to direct the disposition of: Logos Global: 0 Logos Global GP: 0 Global Fund: 0 Logos GP: 0 Arsani William: 0
	(iv) Shared power to dispose or to direct the disposition of: Logos Global: 1,285,000 Logos Global GP: 1,285,000 Global Fund: 1,285,000 Logos GP: 1,285,000 Arsani William: 1,285,000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Global Fund holds the Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Logos Global Management LP

Signature:	/s/ Arsani William
Name/Title:	Managing Partner
Date:	04/01/2026

Logos Global Management GP LLC

Signature:	/s/ Arsani William
Name/Title:	Managing Member
Date:	04/01/2026

Logos Global Master Fund LP

Signature:	/s/ Arsani William
Name/Title:	Managing Member of Logos GP LLC, General Partner of Logos Global Master Fund LP
Date:	04/01/2026

Logos GP LLC

Signature:	/s/ Arsani William
Name/Title:	Managing Member
Date:	04/01/2026

Arsani William

Signature:	/s/ Arsani William
Name/Title:	Reporting person
Date:	04/01/2026

Exhibit Information

EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G